


Claim amendments

1. - 52. (canceled)

53. (currently amended) A compound of formula Ib or formula IIb:



where:

n is an integer of 0 to 4 in Formula Ib, and is an integer of 0 to 2 in Formula IIb;

Z is N or C(R⁸);

each R¹ is independently optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR⁹, -SR⁹, -NR⁹R¹⁰, -NR⁹(CH₂)₁₋₆C(=O)OR¹⁰, -C(=O)R⁹, C(=O)OR⁹, -C(=O)NR⁹R¹⁰, -OC(=O)R⁹, -SO₂R⁹, -OSO₂R⁹, -SO₂NR⁹R¹⁰, -NR⁹SO₂R¹⁰ or -NR⁹C(=O)R¹⁰, where R⁹ and R¹⁰ are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₁₋₂ alkyl)₂, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R⁹ and R¹⁰ together are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(CH₂)₁₋₆C(=O)OR (where R is hydrogen or lower alkyl) or N-(optionally substituted C₁₋₂ alkyl) group, or in Formula I, n=2 and the two R¹'s together constitute =O,

R^2 , R^3 and R^8 are independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), $-\text{CF}_3$, halogen, nitro, $-\text{CN}$, $-\text{OR}^9$, $-\text{SR}^9$, $-\text{NR}^9\text{R}^{10}$, $-\text{NR}^9(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{OR}^{10}$, $-\text{C}(=\text{O})\text{R}^9$, $-(=\text{O})\text{OR}^9$, $-\text{C}(=\text{O})\text{NR}^9\text{R}^{10}$, $-\text{OC}(=\text{O})\text{R}^9$, $-\text{SO}_2\text{R}^9$, $-\text{OSO}_2\text{R}^9$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{10}$ or $-\text{NR}^9\text{C}(=\text{O})\text{R}^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $\text{N}(\text{C}_{1-2}\text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(\text{CH}_2)_{4-6}$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N- $(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{OR}$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group,

R^4 and R^5 are independently hydrogen, lower alkyl optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aryl(lower alkyl), or, together, are $-(\text{CH}_2)_{2-4}$, and

R^6 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), $-\text{C}(=\text{O})\text{R}^{11}$, $-\text{C}(=\text{O})\text{OR}^{11}$, $-\text{C}(=\text{O})\text{NR}^{11}\text{R}^{12}$, $-\text{SO}_2\text{R}^{11}$, or $-\text{SO}_2\text{NR}^{11}\text{R}^{12}$, where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are $-(\text{CH}_2)_{4-6}$,
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

54. (canceled)

55. (currently amended) A compound of claim 53 where Z is CH R^8 is H.

56. (previously presented) A compound of claim 53 where the compound is a compound of Formula Ib,
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

57. (previously presented) A compound of claim 53 where the compound is a compound of Formula IIb,
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

58. (previously presented) A compound of claim 53 where each R^1 is independently, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

59. (previously presented) A compound of claim 53 where $n=0$.

60. (previously presented) A compound of claim 53 where R^2 is optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9(CH_2)_{1-6}C(=O)OR^{10}$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N- $(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group.

61. (previously presented) A compound of claim 53 where R^2 is $-NR^9R^{10}$, wherein R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), benzyl, optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N- $(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group.

62. (previously presented) A compound of claim 53 where R^2 is hydrogen.

63. (currently amended) A compound of claim 53 where the compound is a compound of formula Ib,
where Z is $\underline{C-H-R^8}$ is H, $n=0$, and R^2 is hydrogen,
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.


64. (previously presented) A compound of claim 53 where R^3 is optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, or $-C(=O)NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), $N-(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group.

65. (previously presented) A compound of claim 53 where R^3 is hydrogen.

66. (previously presented) A compound of claim 53 where R^4 and R^5 are independently hydrogen or lower alkyl.

67. (previously presented) A compound of claim 53 where R^6 is hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-SO_2R^{11}$, or $-SO_2NR^{11}R^{12}$, where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, cycloalkyl, cycloalkyl(lower alkyl), aryl, heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are $-(CH_2)_{4-6}$.

68. (previously presented) A compound of claim 53 where:



m is an integer of 0 to 4;

R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, $-CN$, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, $-NR^{15}SO_2R^{16}$ or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, $-CF_3$, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl,

optionally substituted heteroaryl(lower alkyl), or, together, are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group, and

each R¹⁴ is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, -CF₃, -OR¹⁷, -NR¹⁷R¹⁸, -C(=O)R¹⁷, -C(=O)OR¹⁷, -C(=O)NR¹⁷R¹⁸, where R¹⁷ and R¹⁸ are independently, hydrogen, lower alkyl, alkenyl, alkynyl, -CF₃, optionally substituted heterocycloalkyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or, together, are $-(CH_2)_{4-6}$, optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.

69. (previously presented) A compound of claim 68 where R¹³ is hydrogen, optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR¹⁵, -SR¹⁵, -NR¹⁵R¹⁶, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)NR¹⁵R¹⁶, -OC(=O)R¹⁵, -SO₂R¹⁵, -SO₂NR¹⁵R¹⁶, or -NR¹⁵C(=O)R¹⁶, where R¹⁵ and R¹⁶ are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.

70. (previously presented) A compound of claim 69 where R¹³ is optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR¹⁵, -SR¹⁵, -NR¹⁵R¹⁶, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)NR¹⁵R¹⁶, -OC(=O)R¹⁵, -SO₂R¹⁵, -SO₂NR¹⁵R¹⁶, or -NR¹⁵C(=O)R¹⁶, where R¹⁵ and R¹⁶ are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.

71. (previously presented) A compound of claim 70 where R¹³ is independently selected from aryl, substituted aryl, optionally substituted heteroaryl, halogen, -CF₃, -CN, -OR¹⁵, or -C(=O)OR¹⁵, where R¹⁵ is hydrogen, lower alkyl or optionally substituted aryl.

72. (previously presented) A compound of claim 68 where each R^{14} is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-CF_3$, $-OR^{17}$, $-NR^{17}R^{18}$, $-C(=O)R^{18}$, $-C(=O)OR^{18}$, and $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.

73. (previously presented) A compound of claim 68 where each R^{14} is independently selected from halogen, $-CF_3$, $-OR^{17}$, $-C(=O)OR^{17}$, or $-OCH_2C(=O)OR^{17}$, where R^{17} is hydrogen, lower alkyl or optionally substituted aryl.

74. (previously presented) A compound of claim 68 where R^{13} is not hydrogen, and m is an integer of 1 to 2.

75. (previously presented) A compound of claim 74 where m is 1.

76. (previously presented) A compound of claim 68 where R^2 and R^3 are independently selected from hydrogen, lower alkyl, and halogen.

77. (previously presented) A compound of claim 53 that is selected from the group consisting of:

- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-chlorophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3,4-dichlorophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-chloro-4-hydroxyphenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(4-(trifluoromethyl)phenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(4-chlorophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-bromophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-cyanophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(2,4-dichlorophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(4-iodophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-iodophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-(trifluoromethoxy)phenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-(methylethyl)phenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(3-methylphenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[e]1,4-dioxan-6-yl-N-[(2-iodophenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-[(3-(trifluoromethyl)phenyl)amino]carbonyl} carboxamide;
- 2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-[(3-(trifluoromethylthio)phenyl)amino]carbonyl} carboxamide;

2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-ethylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-ethoxyphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-(methylethoxy)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-phenylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-(tert-butyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-chloro-4-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-iodo-4-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(4-methyl-3-(trifluoromethyl)phenyl)amino]carbonyl}-
carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(4-fluoro-3-(trifluoromethyl)phenyl)amino]carbonyl}-
carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3,4-bis(trifluoromethyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3,5-bis(trifluoromethyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-phenoxyphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-nitrophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3,5-dichlorophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-acetylphenyl)amino]carbonyl}carboxamide;
methyl 3-{{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}benzoate;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-(1H-1,2,3,4-tetrazol-5-yl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-ethynylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-chloro-2-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(5-chloro-2-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(5-iodo-2-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(5-chloro-2-methoxyphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-chloro-2,6-diethylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{{[(3-(1,3-thiazol-2-yl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-(2-thienyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-(3-thienyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-(2-furyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(3-(2-pyridyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{{[(4-(1H-1,2,3,4-tetrazol-5-yl)phenyl)amino]carbonyl}carboxamide;

methyl 5-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-bromobenzoate;
3-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-5-(trifluoromethyl)benzoic acid;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-[[[3-hydroxy-5-(trifluoromethyl)phenyl]amino]carbonyl]-
carboxamide;
5-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-bromobenzoic acid;
4-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-chlorophenyl acetate;
4-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-chlorophenyl methyl propane-
1,3-dioate;
2-[(4-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-chlorophenyl]oxycarbonyl]-
acetic acid;
methyl 2-(4-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-chlorophenoxy)-
acetate;
2-(4-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-chlorophenoxy)acetic acid;
phenylmethyl 2-(4-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-chloro-
phenoxy)acetate;
4-[[[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino]-2-chlorobenzoic acid;
5-[[[(2H,3H-benzo[3,4-e]1,4-dioxin-6-ylcarbonylamino)carbonyl]amino]-2-chlorobenzoic acid;
4-[[[(2H,3H-benzo[3,4-e]1,4-dioxin-6-ylcarbonylamino)carbonyl]amino]benzoic acid;
3-[[[(2H,3H-benzo[3,4-e]1,4-dioxin-6-ylcarbonylamino)carbonyl]amino]benzoic acid;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-[[[(2-chloro(4-pyridyl))amino]carbonyl]carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-[[[(6-chloro-4-methylpyrimidin-2-yl)amino]carbonyl]carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-[[[5-(trifluoromethyl)(1,3,4-thiadiazol-2-yl)]amino]carbonyl]-
carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-[[[(3-chlorophenyl)(methoxymethyl)amino]carbonyl]-
N-(methoxymethyl)carboxamide; and
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-[[[(3-chlorophenyl)amino]carbonyl]-N-[(2-methoxy-
ethoxy)methyl]carboxamide;
and the pharmaceutically acceptable salts thereof, as single stereoisomers or mixtures of stereoisomers.

78. (previously presented) A pharmaceutical composition comprising:

- (a) a therapeutically effective amount of a compound of claim 53; and
- (b) a pharmaceutically acceptable excipient.

79. (canceled)

80. (previously presented) A method of treating an allergic, inflammatory, or autoimmune disease in a mammal, comprising administration to the mammal of a therapeutically effective amount of a compound of claim 53.

81. (withdrawn) The method of claim 80, where the disease is asthma.

82. (withdrawn) The method of claim 80, where the disease is pulmonary fibrosis.

83. (withdrawn) The method of claim 80, where the disease is diabetic nephropathy.

84. (withdrawn) The method of claim 80, where the disease is rheumatoid arthritis.

85. (withdrawn) The method of claim 80, where the disease is restenosis.

86. (withdrawn) The method of claim 80, where the disease is pancreatitis.

87. (withdrawn) The method of claim 80, where the disease is glomerulonephritis.

88. (withdrawn) The method of claim 80, where the disease is atherosclerosis.

89. (withdrawn) The method of claim 80, where the disease is inflammatory bowel disease.

90. (withdrawn) The method of claim 80, where the disease is Crohn's disease.

91. (withdrawn) The method of claim 80, where the disease is transplant rejection.

92. (withdrawn) The method of claim 80, where the disease is associated with lymphocyte and/or monocyte accumulation.

93. - 94. (canceled).